

Late complications following continuous- flow left ventricular assist device impla...

[Health & Medicine](#)



Introduction

Technological advances have allowed for the emergence of newer generation, continuous-flow left ventricular assist devices (LVADs) approved for both bridge-to-transplant (BTT) as well as destination therapy (DT) in patients with end-stage heart failure. As outlined in the Third INTERMACS Annual Report, there has been a recent trend toward a greater number of devices being implanted in patients with an initial strategy of DT support ([1](#)). The Sixth INTERMACS Annual Report quantified further and demonstrated a nearly three-fold increase from 2006–2007 to 2011–2013 (14. 7 and 41. 6%, respectively) ([2](#)). Within this cohort of patients implanted between 2006 and 2010, approximately 80% were deemed INTERMACS level 2 (progressive decline), 3 (stable but inotrope-dependent), or 4 (recurrent, advanced heart failure) ([1](#), [3](#)), and as they did not represent “crash and burn” patients (INTERMACS level 1), expected short-term survivals were improved ([4](#), [5](#)).

Accordingly, while early complications following LVAD implantation have been extensively described and have been shown to greatly impact perioperative morbidity and mortality ([6](#)–[8](#)), it is reasonable to expect that the influence of late adverse events will be increasingly more relevant given the changing landscape of these implantable circulatory support devices. The following review will explore the long term, systemic effects of prolonged, continuous-flow LVAD support (device failures, bleeding, right ventricular dysfunction, infection, aortic valve pathology, and

thromboembolic events) and briefly describe the most common management strategies employed in each scenario.

Technical, Device Failures

Failure of modern, continuous-flow LVADs is exceedingly rare but can involve any component of the device (i. e., pump, controller, or power source). It is critically important that an emergency card is visible at all times when a patient is discharged to home with a LVAD. This will provide invaluable information to first responders in cases of device failure. More specifically, problems with the power source can typically be mitigated by a VAD coordinator or outpatient nurse as they are easily exchangeable without the need for an invasive procedure.

If, however, the pump or the internal portion of the cable is the culprit, an emergent and operative exchange is required. In these instances, profound cardiogenic shock can develop and temporary extracorporeal support might be necessary. The reported incidence of pump thrombosis in modern, continuous-flow devices ranges from 0. 01 to 0. 11 events per patient-year, but these figures likely represent underestimates as clinically silent thrombi often go undetected and not all devices are interrogated following explant ([8 – 10](#)). Factors, such as atrial fibrillation, sub-therapeutic systemic anticoagulation, and infection, have been associated with increases in device thrombosis.

Since 2011, the incidence of HeartMate II ® (Thoratec Corp., Pleasanton, CA) thrombosis has seen a dramatic increase from roughly 2 to 8% by January 2013 ([9](#)). Participating investigators theorized that this phenomenon was <https://assignbuster.com/late-complications-following-continuous-flow-left-ventricular-assist-device-implantation/>

largely attributable to the “ bearing-fibrin deposition theory”, which occurs in three distinct phases: (1) an initial phase characterized by hemolysis and thrombus deposition (termed “ thrombus formation”); (2) “ incomplete thrombus” resulting in red-cell destruction and abnormalities in LVAD performance; and (3) “ complete thrombosis” culminating in device failure ([9](#)). While no unifiable factors were identified, flow reduction, whether due to arrhythmia, aortic regurgitation, or outflow obstruction, is an important element of the pathophysiology.

While there remains no consensus regarding the most sensitive and specific marker for early detection of imminent pump thrombosis, some have proposed a serum lactate dehydrogenase (LDH) level $> 4 \times$ normal ([10](#)) in combination with suspicious echocardiographic findings. While this value might capture patients with frank thrombosis, it might miss more subtle, earlier indicators of an impending problem at a time in which intervention might prove beneficial. Accordingly, LDH values $> 2.5 \times$ normal should prompt further interrogation with additional serum values [hemoglobin, haptoglobin, creatinine, total bilirubin, and international normalized ratio (INR)], chest X-ray, and a transesophageal echocardiogram. The latter can be utilized to evaluate the position of the cannula in respect to the ventricular walls and mitral valve. Additionally, if the aortic valve continues to open in response to incremental increases in the LVAD speed (ramp test), thus denoting incomplete emptying of the left ventricle, pump thrombosis should be suspected.

In the initial stages of device thrombosis, and assuming patient stability, non-operative management should be attempted. The patient should be started on a heparin infusion to halt propagation of the thrombus and to augment fibrinolysis. Active resuscitation should also be pursued, with or without force diuresis, to combat the detrimental effects of hemolysis on renal function. The patient should be closely monitored in a cardiac intensive care unit for signs of decompensation that might require urgent surgical management. In order to minimize the risk of pump thrombosis, patients should undergo a ramp study during their index hospitalization to provide a baseline for further evaluations. Anticoagulant and antiplatelet therapy should be implemented with an INR goal of 2-3.

In a large study that retrospectively examined approximately 1, 200 devices, the rate of driveline fracture was 9. 2% ([11](#)). A majority of these cases (87%) were isolated to the external portion of the cable and reinforcement was successful in most instances (76%) ([11](#)).

Bleeding

Hemorrhage is one of the most common and challenging early and late complications associated with LVADs. The incidence of bleeding, whether requiring reoperation or red cell transfusion, is 0. 16-2. 45 events per patient-year ([12](#), [13](#)). The etiology of these events is multifactorial and includes: (1) management with systemic anticoagulation to diminish the risks of pump thrombosis and thromboembolic phenomena, (2) acquired von Willebrand Syndrome due to the non-physiologic, high-shear stress associated with the low-pulse pressures of continuous-flow devices ([14](#), [15](#))

), and (3) the appearance of arteriovenous malformations (AVMs) ([16](#) , [17](#)). While a majority of early episodes involves intrathoracic and/or mediastinal hemorrhage, the importance of these as causative factors diminishes over time. Conversely, the gastrointestinal (GI) tract is the principal source of late hemorrhage and, accordingly, a familiar effector of hospital readmission ([14](#) , [18](#)). Several studies have demonstrated a growing rate of clinically relevant GI bleeds with the advent of continuous-flow devices ([19](#) , [20](#)). While this association is most likely a combined result of manufacturer recommendations and guidelines of the HeartMate II Pivotal Trial to utilize antiplatelet medications and anticoagulants in LVAD patients to mitigate the up-regulation of the coagulation cascade, the observed rate was higher than would be attributable to systemic therapies alone ([19](#)).

Awareness of additional mechanisms that may contribute to this increased incidence of GI events has been the focus of several recent studies ([14](#) , [17](#)). A sub-analysis of the HVAD BTT and CAP trials demonstrated a 15. 4% incidence of GI bleeding with 86. 1% of these events occurring > 30 days from the initial operation ([14](#)). It is important to note that while the mean INRs were higher in those experiencing a bleed (2. 4 vs. 1. 6, $p < 0. 0001$), a frank lesion, with an AVM being the most common, was identified as the cause of hemorrhage in 78% of the events ([14](#)). The pathophysiology associated with the development of these malformations is similar to the mechanism implicated in severe aortic stenosis ([21](#)). More specifically, a decrease in pulse pressure in these continuous-flow devices could result in relative splanchnic hypoperfusion and increased vessel friability. Another proposed theory to explain the high frequency of AVMs in this demographic

involves the influence of increased intraluminal pressures, simultaneous vascular smooth muscle contractions, and subsequent relaxations of the bowel wall smooth muscle ([16](#) , [17](#)).

In addition to adversely affecting vessel integrity, continuous-flow LVADs have been associated with acquired von Willebrand Syndrome ([15](#) , [20](#) , [22](#)). The biologic activity of von Willebrand factor (vWF) depends upon the cleavage of this molecule at a specific site by the ADAMTS13 metalloprotease and in order to promote normal coagulation, it is crucial to maintain equilibrium of the vWF multimer size. Studies have demonstrated that in situations of high-shear stress, the vWF multimers can undergo a conformational change, leading to an over-exposure of the cleavage domain. The shear forces on the artificial surfaces of these mechanical devices may deplete these larger multimers due to aberrant cleavage by ADAMTS13 and result in bleeding abnormalities ([15](#) , [20](#) , [22](#)).

Most GI bleeds require hospitalization, cessation of anticoagulation/antiplatelet therapies, institution of acid-reflux agents, and close hemodynamic and laboratory monitoring. Patients should be promptly evaluated by a Gastroenterologist for possible endoscopic management. Fortunately, several large studies have established that surgical intervention is rarely, if ever, a component of the treatment algorithm ([14](#)). These events are associated, however, with readmissions, non-device related infections, and subsequent thromboembolic complications ([13](#) , [14](#)).

Several studies have supported a reduction in the target INR to 1. 5-2. 5 following a major GI bleed as most events are associated with an INR $\geq 2. 5$ (

[23](#)). Unless the patient has had multiple life-threatening hemorrhagic events, complete cessation of anticoagulants and antiplatelet therapies is not recommended. In a meta-analysis evaluating risk factors associated with GI hemorrhage, nine of the studies included reported that a majority of the HeartMate II patients had therapeutic or sub-therapeutic INRs ([24](#)).

Right Ventricular Dysfunction

Right ventricular dysfunction occurs in 9–44% of patients following LVAD implantation and is a significant contributor of short- and long-term morbidity and mortality ([25](#) – [27](#)). An initial examination into the comparative incidence of this condition in patients managed with pulsatile and continuous-flow device demonstrated no significant difference ([28](#)). Acute right heart failure is typically attributable to pre-LVAD organ system dysfunction [as indicated by the need for mechanical ventilation ([29](#)) or elevations in serum bilirubin and/or creatinine ([30](#))] and/or marginal right ventricular function at the time of implant ([27](#), [29](#)).

A more insidious, chronic form of right ventricular dysfunction has also been identified, but its pathogenesis is poorly characterized. Multiple studies have demonstrated a leftward excursion of the intraventricular septum due to a reduction in left ventricular pressure and augmentation of right ventricular preload in patients supported by a LVAD ([30](#), [31](#)). These physiologic alterations are typically well tolerated and can even create a favorable pressure profile. In selected patients with marginal right ventricular function, however, even small variations in right-sided compliance can result in an inability to tolerate an increase in venous return. Conventional management

strategies involve the assessment of flow through the device to normalize septal shift and the introduction of agents to minimize right ventricular afterload. The need for biventricular support in patients with severe right-sided impairment confers a considerably worse prognosis ([27](#)). In BTT patients with right ventricular dysfunction recalcitrant to medical management, heart transplantation should be strongly considered to avoid further deterioration of end-organ function.

Infection

As per the INTERMACs Registry, LVAD-associated infections are categorized as follows: (1) *localized non-device infection* – infection involving an organ or region without evidence of systemic involvement; (2) *pump infection* – infection involving any component of the pump (pump or inflow or outflow cannulae); and (3) *percutaneous site and/or pocket infection* – positive culture from the tissue surrounding either the external portion of the driveline or the housing of the device. The latter has been largely attributed to trauma around the exit site that disrupts the tissue-line interface ([32](#)). In a large institutional series of 143 HeartMate II patients, driveline infections were diagnosed in approximately 12% of the population ([33](#)). The odds of developing an infection increased approximately 4% for each additional month of LVAD support ([33](#)). Progression to pocket or pump involvement was rare.

The incidence of driveline, pump pocket, or pump infection has diminished with the advent of newer generation, smaller axial-flow LVADs (e. g., driveline infections: 0. 37 vs. 3. 49 events per patient-year in HeartMate I

and HeartMate II devices, respectively) ([34](#)). Furthermore, while the exact etiology is unknown, substantial reductions in infectious complications have also been appreciated in the recent era of continuous-flow implants (10. 0 vs. 1. 3 events per 100 patient-months, $p < 0. 001$) ([2](#)). Most cases are successfully treated with antibiotic therapy and reinforcement of the exit site. More complex infections required surgical debridement in addition to medical management. Despite their varying clinical implications, these infections should not be trivialized as they are associated with costly readmissions and increased length of stay ([32](#)).

Patients should be educated on the importance of recognizing and reporting any traumatic events associated with the driveline as even small shear forces are capable of inciting an infectious complication. Some infections can be treated on an outpatient bases with a combination of intravenous and oral antibiotics that cover the most common pathogens, namely *Staphylococcus* species ([32](#), [33](#)). In patients who were present with noticeable cellulitis and other markers of infection, e. g., fever and leukocytosis, hospital admission and further workup are more appropriate. Blood cultures, aspirates for Gram stain and culture, and tissue samples should be collected if clinically indicated. If a deeper infection is suspected, abdominal ultrasound or CT imaging might be warranted.

If conservative management is not successful, then complete circumferential excision of all neo-epithelized tissue is required. Excision should continue until a tight adherence between the driveline and surrounding tissue is apparent. If the infection involves the pump pocket, external drainage can be

attempted, but is often times unsuccessful. Surgical management of these infections can be difficult and multiple operations might be required to salvage the device.

Aortic Valve Pathology

LVADs efficiently unload the left ventricle and diminish opening/closing of the aortic valve, which can result in progressive degeneration and a variety of valvular pathologies ([35](#) - [37](#)). This untoward consequence of chronic support can have deleterious effects on end-organ function and complicate cardiac recovery. The aortic valve is especially susceptible to acquired defects as its opening is entirely dependent upon forward flow from the left ventricle.

In a small series of patients with a mean LVAD time of approximately 1 year, commissural fusion was evident in all but one patient ([38](#)). The number of patients experiencing any aortic valve opening on echocardiogram diminished as the duration of support increased, with less than 50% having any valvular motion at 1 year ([38](#)). These morphological changes commonly resulted in mild to moderate central aortic regurgitation. Extrapolating from the heart failure population in which a diminished cardiac-output results in continued leaflet co-aperture, it has been postulated that continuous-flow LVADs create an environment of minimal-antegrade blood flow across the aortic valve ([39](#)). Furthermore, due to the placement of the outflow cannula in the ascending aorta, the closed valve is constantly exposed to a systolic pressure ([40](#)).

Device implantation can also result in a worsening of valvular competence, especially in patients with pre-existing aortic insufficiency ([40](#), [41](#)). Due to the small size of the outflow cannula relative to the native aorta, higher velocities are required to maintain physiologic flow rates ([42](#)). This can produce areas of high-shear stress and initiate a cascade of cellular events which culminates in aortic wall atrophy and sinus dilatation ([37](#)). These alterations might have a more profound effect in smaller patients with presumably narrower aortic diameters. Regardless, regurgitant flow can lead to further ventricular dilatation, increased pump work, and systemic hypoperfusion.

The clinical ramifications of these valvular abnormalities is currently unknown. It is clear, however, that aortic valve disease in patients not destined for heart transplantation can lead to further deterioration in ventricular function and make device explantation less likely. Thus, there is a growing body of literature supporting ramp studies at the time of implant to ensure some aortic valve opening to reduce the long-term implications of prolonged valve closure ([43](#)). In LVAD candidates with baseline regurgitation or stenosis, concomitant aortic valve procedures should be considered. In cases of mild or worse regurgitation, a coaptive stitch can be attempted to regain valve competence. If the native valve cannot be repaired, a bio-prosthesis should be employed to restore proper valve mechanics.

Thromboembolic Events

As previously mentioned, continuous-flow devices alter the equilibrium of the coagulation cascade and can predispose patients to thromboembolic

phenomenon. It was initially believed that the blood-biomaterial interaction within the LVAD was the main stimulus for these findings ([44](#)), but surface modifications did not appear to alleviate the problem ([45](#)). More contemporary mechanisms involve the influence of the rotational flow of blood through the pump on thrombus formation. Additional patient-specific factors, including preoperative atrial fibrillation, have been shown to increase the risk for post-LVAD thromboembolic events ([46](#)).

While the true incidence of thromboembolic disease is hard to approximate given that confirmatory radiographic studies are typically only obtained in patients with frank neurologic impairment, series have estimated that this condition affects 10–17% of patients over the life time of their device ([47](#), [48](#)). These figures likely underestimate the true impact of LVADs on embolic formation as evident by a limited study which identified microembolic disease via transcranial Doppler in 20 out of 23 continuous-flow LVAD patients ([45](#)). The nidus of these thrombi is variable but the influence of aortic valve opening/closing on aortic root stagnation could emerge as an important factor in newer generation devices. To combat thrombus formation, most patients are administered a combination of anticoagulants and antiplatelet agents. Due to an increased risk of GI bleeding associated with greater periods of support, several studies have demonstrated acceptable thromboembolic protection with a more liberal anticoagulation strategy ([49](#)).

Conclusion

Continuous-flow LVADs offer patients with advanced heart failure a viable option for prolonged support. As a growing number of patients are maintained on these devices for longer periods, the impact of late complications on outcomes will become increasingly more relevant. Providers should be aware of these potentially morbid events as prompt diagnosis and treatment are critical.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Abbreviations

BTT, bridge-to-transplant; DT, destination therapy, GI, gastrointestinal, LVAD, left ventricular assist devices, vWF: von Willebrand factor.

References

1. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, et al. Third INTERMACS annual report: the evolution of destination therapy in the United States. *J Heart Lung Transplant* (2011)30 (2): 115–23. doi: 10.1016/j.healun.2010.12.001

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

2. Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, et al. Sixth INTERMACS annual report: a 10, 000-patient database. *J Heart Lung Transplant* (2014)33 (6): 555–64. doi: 10.1016/j.healun.2014.04.010
<https://assignbuster.com/late-complications-following-continuous-flow-left-ventricular-assist-device-implantation/>

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

3. Warner-Stevenson L. The evolving role of mechanical circulatory support in advanced heart failure. In: Frazier OH, Kirklin JH, editors. *ISHLT Monograph Series: Mechanical Circulatory Support*. Elsevier (2006). p. 181-203.

[Google Scholar](#)

4. Yoshioka D, Sakaguchi T, Saito S, Miyagawa S, Nishi H, Yoshikawa Y, et al. Predictor of early mortality for severe heart failure patients with left ventricular assist device implantation: significance of INTERMACS level and renal function. *Circ J* (2012)76 (7): 1631-8. doi: 10.1253/circj.CJ-11-1452

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

5. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, et al. Second INTERMACS annual report: more than 1, 000 primary left ventricular assist device implants. *J Heart Lung Transplant* (2010)29 (1): 1-10. doi: 10.1016/j.healun.2009.10.009

[CrossRef Full Text](#) | [Google Scholar](#)

6. Borgi J, Tsouris A, Hodari A, Cogan CM, Paone G, Morgan JA. Significance of postoperative acute renal failure after continuous-flow left ventricular assist device implantation. *Ann Thorac Surg* (2013)95 (1): 163-9. doi: 10.1016/j.athoracsur.2012.08.076

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

7. Kavarana MN, Pessin-Minsley MS, Urtecho J, Catanese KA, Flannery M, Oz MC, et al. Right ventricular dysfunction and organ failure in left ventricular assist device recipients: a continuing problem. *Ann Thorac Surg* (2002)73 (3): 745–50. doi: 10.1016/S0003-4975(01)03406-3

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

8. Eckman PM, John R. Bleeding and thrombosis in patients with continuous-flow ventricular assist devices. *Circulation* (2012)125 (24): 3038–47. doi: 10.1161/CIRCULATIONAHA.111.040246

[CrossRef Full Text](#) | [Google Scholar](#)

9. Starling RC, Moazami N, Silvestry SC, Ewald G, Rogers JG, Milano CA, et al. Unexpected abrupt increase in left ventricular assist device thrombosis. *N Engl J Med* (2014)370 (1): 33–40. doi: 10.1056/NEJMoa1313385

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

10. Uriel N, Han J, Morrison KA, Nahumi N, Yuzefpolskaya M, Garan AR, et al. Device thrombosis in HeartMate II continuous-flow left ventricular assist devices: a multifactorial phenomenon. *J Heart Lung Transplant* (2014)33 (1): 51–9. doi: 10.1016/j.healun.2013.10.005

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

11. Puehler T, Ensminger S, Schoenbrodt M, Börgermann J, Rehn E, Hakim-Meibodi K, et al. Mechanical circulatory support devices as destination

therapy-current evidence. *Ann Cardi thorac Surg* (2014)3 (5): 513-24. doi: 10.3978/j. issn. 2225-319X. 2014. 08. 20

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

12. Swetz KM, Freeman MR, Mueller PS, Park SJ. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. *J Heart Lung Transplant* (2010)29 (9): 1081. doi: 10.1016/j.healun.2010.04.024

[CrossRef Full Text](#) | [Google Scholar](#)

13. Stulak JM, Lee D, Haft JW, Romano MA, Cowger JA, Park SJ, et al. Gastrointestinal bleeding and subsequent risk of thromboembolic events during support with a left ventricular assist device. *J Heart Lung Transplant* (2014)33 (1): 60-4. doi: 10.1016/j.healun.2013.07.020

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

14. Goldstein DJ, Aaronson KD, Tatooles AJ, Silvestry SC, Jeevanandam V, Gordon R, et al. Gastrointestinal bleeding in recipients of the HeartWare ventricular assist system. *JACC Heart Fail* (2015)3 (4): 303-13. doi: 10.1016/j.jchf.2014.11.008

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

15. Crow S, Chen D, Milano C, Thomas W, Joyce L, Piacentino V 3rd, et al. Acquired von Willebrand syndrome in continuous-flow ventricular assist

device recipients. *Ann Thorac Surg* (2010)90 (4): 1263-9. doi: 10.1016/j.athoracsur.2010.04.099

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

16. Letsou GV, Shah N, Gregoric ID, Myers TJ, Delgado R, Frazier OH. Gastrointestinal bleeding from arteriovenous malformations in patients supported by the Jarvik 2000 axial-flow left ventricular assist device. *J Heart Lung Transplant* (2005)24 (1): 105-9. doi: 10.1016/j.healun.2003.10.018

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

17. John R, Boyle A, Pagani F, Miller L. Physiologic and pathologic changes in patients with continuous-flow ventricular assist devices. *J Cardiovasc Transl Res* (2009)2 (2): 154-8. doi: 10.1007/s12265-009-9092-y

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

18. Forest SJ, Bello R, Friedmann P, Casazza D, Nucci C, Shin JJ, et al. Readmissions after ventricular assist device: etiologies, patterns, and days out of hospital. *Ann Thorac Surg* (2013)95 (4): 1276-81. doi: 10.1016/j.athoracsur.2012.12.039

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

19. Crow S, John R, Boyle A, Shumway S, Liao K, Colvin-Adams M, et al. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. *J Thorac Cardiovasc Surg* (2009)137 (1): 208-15. doi: 10.1016/j.jtcvs.2008.07.032

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

20. Uriel N, Pak SW, Jorde UP, Jude B, Susem S, Vincentelli A, et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. *J Am Coll Cardiol* (2010)56 (15): 1207-13. doi: 10.1016/j.jacc.2010.05.016

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

21. Heyde E. Gastrointestinal bleeding in aortic stenosis. *N Engl J Med* (1958)259 : 196. doi: 10.1056/NEJM195807242590416

[CrossRef Full Text](#) | [Google Scholar](#)

22. Geisen U, Heilmann C, Beyersdorf F, Benk C, Berchtold-Herz M, Schlensak C, et al. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. *Eur J Cardiothorac Surg* (2008)33 (4): 679-84. doi: 10.1016/j.ejcts.2007.12.047

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

23. Boyle AJ, Russell SD, Teuteberg JJ, Slaughter MS, Moazami N, Pagani FD, et al. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. *J Heart Lung Transplant* (2009)28 (9): 881-7. doi: 10.1016/j.healun.2009.05.018

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

24. Draper KV, Huang RJ, Gerson LB. GI bleeding in patients with continuous-flow left ventricular assist devices: a systematic review and meta-analysis.

Gastrointest Endosc (2014)80 (3): 435. e-46. e. doi: 10. 1016/j. gie. 2014.

03. 040

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

25. Ochiai Y, McCarthy PM, Smedira NG, Banbury MK, Navia JL, Feng J, et al.

Predictors of severe right ventricular failure after implantable left ventricular assist device insertion: analysis of 245 patients. *Circulation* (2002)106 (12 Suppl 1): I198-202.

[PubMed Abstract](#) | [Google Scholar](#)

26. Dang NC, Topkara VK, Mercando M, Kay J, Kruger KH, Aboodi MS, et al.

Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure. *J Heart Lung Transplant* (2006)25 (1): 1-6. doi: 10. 1016/j. healun. 2005. 07. 008

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

27. Fitzpatrick JR 3rd, Frederick JR, Hsu VM, Kozin ED, O'Hara ML, Howell E, et al.

Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. *J Heart Lung Transplant* (2008)27 (12): 1286-92. doi: 10. 1016/j. healun. 2008. 09. 006

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

28. Patel ND, Weiss ES, Schaffer J, Ullrich SL, Rivard DC, Shah AS, et al. Right heart dysfunction after left ventricular assist device implantation: a comparison of the pulsatile HeartMate I and axial-flow HeartMate II devices. *Ann Thorac Surg* (2008)86 (3): 832–40. doi: 10.1016/j.athoracsur.2008.05.016

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

29. Kormos RL, Teuteberg JJ, Pagani FD, Russell SD, John R, Miller LW, et al. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. *J Thorac Cardiovasc Surg* (2010)139 (5): 1316–24. doi: 10.1016/j.jtcvs.2009.11.020

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

30. Matthews JC, Koelling TM, Pagani FD, Aaronson KD. The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. *J Am Coll Cardiol* (2008)51 (22): 2163–72. doi: 10.1016/j.jacc.2008.03.009

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

31. Topilsky Y, Hasin T, Oh JK, Borgeson DD, Boilson BA, Schirger JA, et al. Echocardiographic variables after left ventricular assist device implantation associated with adverse outcome. *Circ Cardiovasc Imaging* (2011)4 (6): 648–61. doi: 10.1161/CIRCIMAGING.111.965335

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

<https://assignbuster.com/late-complications-following-continuous-flow-left-ventricular-assist-device-implantation/>

32. Zierer A, Melby SJ, Voeller RK, Guthrie TJ, Ewald GA, Shelton K, et al.

Late-onset driveline infections: the Achilles' heel of prolonged left ventricular assist device support. *Ann Thorac Surg* (2007)84 (2): 515-20. doi: 10.1016/j.athoracsur. 2007. 03. 085

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

33. Sharma V, Deo SV, Stulak JM, Durham LA 3rd, Daly RC, Park SJ, et al.

Driveline infections in left ventricular assist devices: implications for destination therapy. *Ann Thorac Surg* (2012)94 (5): 1381-6. doi: 10.1016/j.athoracsur. 2012. 05. 074

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

34. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. *N Engl J Med* (2009)361 (23): 2241-51. doi: 10.1056/NEJMoa0909938

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

35. John R, Mantz K, Eckman P, Rose A, May-Newman K. Aortic valve pathophysiology during left ventricular assist device support. *J Heart Lung Transplant* (2010)29 (12): 1321-9. doi: 10.1016/j.healun. 2010. 06. 006

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

36. Pak SW, Uriel N, Takayama H, Cappleman S, Song R, Colombo PC, et al.

Prevalence of de novo aortic insufficiency during long-term support with left

ventricular assist devices. *J Heart Lung Transplant* (2010)29 (10): 1172-6.
doi: 10.1016/j.healun.2010.05.018

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

37. Cowger J, Pagani FD, Haft JW, Romano MA, Aaronson KD, Koliass TJ. The development of aortic insufficiency in left ventricular assist device-supported patients. *Circ Heart Fail* (2010)3 (6): 668-74. doi: 10.1161/CIRCHEARTFAILURE.109.917765

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

38. Mudd JO, Cuda JD, Halushka M, Soderlund KA, Conte JV, Russell SD. Fusion of aortic valve commissures in patients supported by a continuous axial flow left ventricular assist device. *J Heart Lung Transplant* (2008)27 (12): 1269-74. doi: 10.1016/j.healun.2008.05.029

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

39. Connelly JH, Abrams J, Klima T, Vaughn WK, Frazier OH. Acquired commissural fusion of aortic valves in patients with left ventricular assist devices. *J Heart Lung Transplant* (2003)22 (12): 1291-5. doi: 10.1016/S1053-2498(03)00028-7

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

40. Samuels LE, Thomas MP, Holmes EC, Narula J, Fitzpatrick J, Wood D, et al. Insufficiency of the native aortic valve and left ventricular assist system inflow valve after support with an implantable left ventricular assist system:

<https://assignbuster.com/late-complications-following-continuous-flow-left-ventricular-assist-device-implantation/>

signs, symptoms, and concerns. *J Thorac Cardiovasc Surg* (2001)122 (2): 380-1. doi: 10. 1067/mtc. 2001. 114770

[CrossRef Full Text](#) | [Google Scholar](#)

41. Bryant AS, Holman WL, Nanda NC, Vengala S, Blood MS, Pamboukian SV, et al. Native aortic valve insufficiency in patients with left ventricular assist devices. *Ann Thorac Surg* (2006)81 (2): e6-8. doi: 10. 1016/j. athoracsur. 2005. 08. 072

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

42. May-Newman K, Hillen B, Dembitsky W. Effect of left ventricular assist device outflow conduit anastomosis location on flow patterns in the native aorta. *ASAIO J* (2006)52 (2): 132-9. doi: 10. 1097/01. mat. 0000201961. 97981. e9

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

43. Jorde UP, Uriel N, Nahumi N, Bejar D, Gonzalez-Costello J, Thomas SS, et al. Prevalence, significance, and management of aortic insufficiency in continuous flow left ventricular assist device recipients. *Circ Heart Fail* (2014)7 (2): 310-9. doi: 10. 1161/CIRCHEARTFAILURE. 113. 000878

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

44. Himmelreich G, Ullmann H, Riess H, Rosch R, Loebe M, Schiessler A, et al. Pathophysiologic role of contact activation in bleeding followed by thromboembolic complications after implantation of a ventricular assist

device. *ASAIO J* (1995)41 (3): M790–4. doi: 10.1097/00002480-199507000-00122

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

45. Thoennissen NH, Schneider M, Allroggen A, Ritter M, Dittrich R, Schmid C, et al. High level of cerebral microembolization in patients supported with the DeBakey left ventricular assist device. *J Thorac Cardiovasc Surg* (2005)130 (4): 1159–66. doi: 10.1016/j.jtcvs.2005.02.068

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

46. Stulak JM, Deo S, Schirger J, Aaronson KD, Park SJ, Joyce LD, et al. Preoperative atrial fibrillation increases risk of thromboembolic events after left ventricular assist device implantation. *Ann Thorac Surg* (2013)96 (6): 2161–7. doi: 10.1016/j.athoracsur.2013.07.004

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

47. Goldstein DJ. Worldwide experience with the MicroMed DeBakey ventricular assist device as a bridge to transplantation. *Circulation* (2003)108 (Suppl 1): II272–7. doi: 10.1161/01.cir.0000087387.02218.7e

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

48. Miller LW, Pagani FD, Russell SD, John R, Boyle AJ, Aaronson KD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. *N Engl J Med* (2007)357 (9): 885–96. doi: 10.1056/NEJMoa067758

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

<https://assignbuster.com/late-complications-following-continuous-flow-left-ventricular-assist-device-implantation/>

49. John R, Kamdar F, Liao K, Colvin-Adams M, Miller L, Joyce L, et al. Low thromboembolic risk for patients with the Heartmate II left ventricular assist device. *J Thorac Cardiovasc Surg* (2008)136 (5): 1318-23. doi: 10.1016/j.jtcvs.2007.12.077

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)